News

  • Main
  • /
  • Press-Center
  • /
  • News
  • /
  • Rosneft Top management will finance a research program in cancer cell immune therapy at the Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology

Rosneft Top management will finance a research program in cancer cell immune therapy at the Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology

Igor Sechin told about this on the 26th of January. He noted that the specialists of the Dmitry Rogachev National Research Center have achieved good results in the treatment of children’s cancer for five years — 80% of patients were saved.

"Unfortunately, there is up to 20% of children which are currently considered incurable. And nowhere in the world there are no methods for their treatment. We share the pain of these children and their families. That's why we made the decision to finance from personal funds a research program in cancer cell immune therapy, aimed at the drugs development for treatment of children who are now considered hopeless, "- said the Rosneft CEO. He said that the talk is about developments in genetic modification of immune system cells, targeted therapies, stem cell transplantation.

The Top management of the company will transfer 266 million rubles for realization of a three-year program of cancer research center. 100 million rubles of these will be from own funds of Sechin. The company also intends to negotiate with the Dmitry Rogachev National Research Center on corporate high-tech medical care.

Rosneft has recently paid much attention to the healthcare industry, for example, it is building a multipurpose medical complex in Gelendzhik (total value of 3.5 billion rubles). 

 

 

Source

Back